The Valley Desk

Clinical trial reportJournal of Crohn's & colitisPublished

Safety and tolerability of anti-toll-like receptor 3, monoclonal antibody PRV-300 in patients with moderate-to-severe ulcerative colitis: a randomized phase 1B clinical trial (PULSE)

Read the publication ↗ Open access copy ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

Publication record

Type
Clinical trial report
Venue
Journal of Crohn's & colitis
Published
Subject terms
Humans; Colitis, Ulcerative; Antibodies, Monoclonal; Treatment Outcome; Severity of Illness Index; Double-Blind Method; Adult; Middle Aged; Female; Male; Toll-Like Receptor 3; Antibodies, Monoclonal, Humanized
PubMed ID
42896861
PubMed Central ID
PMC13680009
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal